AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated or synthetic peptide comprising a member selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4, wherein the peptide is an anti-hypertensive agent.

2. (Withdrawn) An isolated or synthetic peptide expressed in a venom of a scorpion, wherein the peptide comprises at least two features selected from the group consisting of: i) lack of Cystein residues and lack of internal disulfide bridges; ii) a molecular signature at a C-terminal ending or portion, described as: Xaa-Pro-Pro or Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue; iii) pairs of amino acid residues effective to form a protective shield against amino-, endo- and carboxi- proteinases enzymes; and iv) Hypotensive effects in vertebrates.

3. (Canceled).

4. (Withdrawn) A nucleic acid molecule encoding the peptide of claim 1.

5. (Withdrawn) The peptide of claim 1, wherein the peptide is produced by recombinant techniques using a viral system, a bacterial system, a fungal system, other prokaryotic systems, other eukaryotic systems or a combination thereof.

6. (Withdrawn) A method for producing an administrable pharmaceutical composition comprising the peptide of claim 1.

7. (Withdrawn) A method for producing a genetically modified virus, bacteria, fungi, plant or any other recombinant techniques using any virus system, any bacterial system, any fungal system or any other prokaryotic or eukaryotic system or combination thereof, in order to use these organisms as excipient or vector for complete, partial or modified sequences of claim 1.

8. (Withdrawn) A pharmaceutical composition comprising an anti-hypertensive amount of the peptide of claim 1.

9. (Withdrawn) A method for labeling and/or chemically modifying a peptide of claim 1.

10. (New) The peptide of claim 1, wherein the peptide is expressed in a venom of a scorpion.

11. (New) The peptide of claim 1, wherein the peptide comprises at least two features selected from the group consisting of: i) a lack of Cystein residues and a lack of internal disulfide bridges; ii) a molecular signature at a C-terminal ending or portion, described as: Xaa-Pro-Pro or Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue; iii) pairs of amino acid residues effective to form a protective shield against amino-, endo- and carboxi- proteinases enzymes; and iv) hypotensive effects in vertebrates.

12. (New) The peptide of claim 1, wherein the peptide is free of Cystein residues and internal disulfide bridges.

13. (New) The peptide of claim 1, wherein the peptide comprises a molecular signature at a C-terminal ending or portion, described as: Xaa-Pro-Pro or Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue.

14. (New) The peptide of claim 1, wherein the peptide comprises pairs of amino acid residues effective to form a protective shield against amino-, endo- and carboxi- proteinases enzymes.

15. (New) The peptide of claim 1, wherein the peptide has a hypotensive effect in vertebrates.